Thermo Fisher Scientific Award –


WALTHAM, Massachusetts, October 6, 2021

WALTHAM, Mass., October 6, 2021 / PRNewswire / – Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher“) announced today that it has priced an offer in the aggregate principal amount of EUR 5.25 billion (the” Offer “) of the following euro denominated banknotes, to be issued by Thermo Fisher Scientific (Finance I) BV, its indirect wholly owned subsidiary financing subsidiary:

  • € 1,750,000,000 in aggregate principal of its 0.800% senior bonds due 2030 (the “2030 bonds”), at the issue price of 99.810% of their principal amount,
  • € 1,500,000,000 in overall principal of its 1.125% senior bonds maturing in 2033 (the “2033 bonds”), at the issue price of 99.732% of their principal amount,
  • € 1,250,000,000 of the overall principal amount of its 1.625% senior bonds maturing in 2041 (the “2041 bonds”), at the issue price of 98.171% of their principal amount, and
  • € 750,000,000 in aggregate principal amount of its 2,000% senior bonds maturing in 2051 (as well as the 2030 bonds, 2033 bonds and 2041 bonds, the “bonds”), at the issue price of 99.331% of their amount main.

The Offer is expected to close on or about October 18, 2021, subject to customary closing conditions. The Notes will be fully and unconditionally guaranteed by Thermo Fisher. The Notes will bear interest on an annual basis.

Thermo Fisher intends to use the net proceeds of the Offering to pay a portion of the cash consideration payable for the ongoing acquisition of PPD, Inc.

The joint bookkeepers of the Offer are Barclays Bank PLC, Morgan Stanley Europe SE, BofA Securities Europe SA, Citigroup Global Markets Europe AG and Mizuho Securities Europe GmbH.

The Offer is being made in accordance with an effective registration statement on Form S-3 filed with the United States Securities and Exchange Commission (the “SEC”). Prospective investors should read the prospectus forming part of this registration statement and the prospectus supplement relating to the Offer and other documents which Thermo Fisher has filed more complete information with the SEC on Thermo Fisher and the Offer. These documents are available free of charge by visiting EDGAR on the SEC’s website at Alternately, Thermo Fisher, the underwriters or any broker participating in the Offer will arrange to send you the prospectus if you request it by calling Barclays Bank PLC at +1 888 603 5847, Morgan Stanley Europe SE at +44 (0) 20 7677 4799, BofA Securities Europe SA on +33 (0) 1 8770 0000, Citigroup Global Markets Europe AG on +1 800 831 9146 or Mizuho Securities Europe GmbH on +49 69 42729 3000.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the Tickets, and there will be no offer, solicitation or sale of the Tickets in any jurisdiction in which such an offer, solicitation or sale. would be illegal.

MiFID II and UK MiFIR – professionals / ECPs only / No PRIIPs or UK PRIIPs KID – The target market for manufacturers (governance of MiFID II and UK MiFIR products) includes only eligible counterparties and professional clients (all distribution channels). No PRIIPs or UK PRIIPs key information document (KID) has been prepared as it is not available for retail sale in the European Economic Area (“EEA”) or UK (“UK”).

This press release is addressed only to specific persons who are natural persons (i) who have professional experience in investment matters falling under Article 19 (5) of the Financial Promotion Act 2000 (Financial Promotion) of 2005, as amended (the “Order”) and qualified investors falling under Article 49 (2) (a) to (d) of the Order and (ii) to whom it may otherwise be legally communicated under the Order (all such persons being together referred to as “the“ Order ”) concerned persons”). This press release should not be used or relied on by persons who are not concerned persons Any investment or investment activity to which this press release relates is accessible only to relevant persons and will only be undertaken with relevant persons. By reading this press release, the reader acknowledges that it is is a person (i) e n outside the UK or (ii) falling into one of the above categories.

This press release is an advertisement and is not a prospectus for the purposes of the Prospectus Regulation (as defined below). A prospectus will be prepared and made available to the public as required and in accordance with the Prospectus Regulations. Investors should not subscribe to any rating mentioned in this press release except on the basis of the information contained in this prospectus. The prospectus, once published, will be available on the Euronext Dublin website at (opens in a new tab).

For these purposes, the term “Prospectus Regulation” means either Regulation (EU) 2017/1129 or Regulation (EU) 2017/1129, as it forms part of UK domestic law under European Union law. (Withdrawal) 2018, as applicable.

In connection with the issuance of the Notes, Morgan Stanley Europe SE (the “Stabilizer Manager”) (or persons acting on behalf of the Stabilizer Manager) may over-allot tickets or effect transactions in order to support the price of ticket market at a higher level than might otherwise prevail. However, there can be no assurance that the Stabilization Officer (or persons acting on behalf of the Stabilization Officer) will take stabilization action. Any stabilization action may begin from the date on which adequate public disclosure of the final terms of the Offer is made and, if commenced, may end at any time, but must be completed no later than no later than early within 30 days of the ticket issue date and 60 days after the ticket issue date. Any stabilization or over-allocation action must be carried out by the stabilization officer (or persons acting on behalf of the stabilization officer) in accordance with all applicable laws and rules.

This press release is issued by Thermo Fisher Scientific (Finance I) BV and contains inside information for the purposes of Article 7 of Market Abuse Regulation (EU) 596/2014 (“MAR”). For MAR purposes, this press release is prepared by Sharon briansky at Thermo Fisher Scientific (Finance I) BV

Thermo Fisher International legal entity identifier is 549300SM0PJC1F3RPL91.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Thermo Fisher’s the intended use of the product. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from currently expected results, including risks and uncertainties relating to capital market conditions, to the ongoing acquisition of PPD. and the completion of the Offer. Important additional factors and information regarding Thermo Fisher’s that could cause actual results to differ materially from those indicated by such forward-looking statements are set out in the dated prospectus February 28, 2019 and dated preliminary prospectus supplement October 4, 2021 related to the Offer, which is filed with the SEC and available in the “Investors” section of our website under the heading “SEC Filings”, and the documents incorporated by reference into the Prospectus and Prospectus Supplement. Although we may choose to update any forward-looking statements at any time in the future, we specifically disclaim any obligation to do so, even if circumstances change and, therefore, you should not rely on such forward-looking statements as representing our views as of any date subsequent to today.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the global leader in the service of science, with annual sales of approximately $ 35 billion. Our mission is to empower our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life science research, solving complex analytical challenges, improving patient diagnostics and therapies, or increasing the productivity of their laboratories, we’re here to support them. Our global team of more than 90,000 colleagues deliver an unrivaled combination of innovative technologies, purchasing convenience and pharmacy services through our industry-leading brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon . For more information, please visit

Media contact details:
Ron O’Brien
Telephone: 781-622-1242
E-mail: [email protected]

Investor contact details:
Rafael Tejada
Telephone: 781-622-1356
E-mail: [email protected]

View original content:

SOURCE Thermo Fisher Scientific

Source link


Leave A Reply